Abstracts Archive - Page 180 of 2607 - ACR Meeting Abstracts

Abstract Number: 1306 • ACR Convergence 2025
Systematic Literature Review of Digital Sleep Outcomes and Endpoints Used to Assess Rheumatoid Arthritis
Anna fishbein¹, Rachel Lawson², Veleka Allen¹, Sophie Wilhelm¹, Tracy Zhang³, Leanne Williams¹, Karen Chandross¹, Godhuli Chatterjee⁴, Markus Kohlmann⁵ and Jeffrey Curtis⁶, ¹Sanofi, Morristown, NJ, ²Sanofi, Earley, United Kingdom, ³Sanofi, Waltham, MA, ⁴Sanofi Healthcare India Private Limited, Mumbai, Maharashtra, India, ⁵Sanofi, Frankfurt, Germany, ⁶University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Sleep disturbances are prevalent among patients with rheumatoid arthritis (RA), posing a substantial burden to patients and are intricately linked to disease activity and…
Abstract Number: 1356 • ACR Convergence 2025
Use of (MSB11456), the first tocilizumab biosimilar approved for rheumatoid arthritis: 6-month data from an international observational study
Jonathan Kay¹, Eugen feist², Ernest Choy³, Joerg Kaufmann⁴, Ernest Wong⁵, Hector Corominas⁶, René-Marc Flipo⁷, Jérôme Avouac⁸, María América López Lasanta⁹, Joelle Monnet¹⁰, Peter Baker¹¹, Maria Romanova Michailidi¹², Fabrizio Dolfi¹¹ and Graziella Pourcel¹³, ¹UMass Chan Medical School, Worcester, MA, ²Helios Department of Rheumatology, Vogelsang-Gommern, Germany, ³Division of Infection and Immunity, CREATE Centre, Cardiff University, Cardiff, United Kingdom, ⁴NA, Ludwigsfelde, Germany, ⁵Portsmouth Hospitals University NHS Trust, Portsmouth, United Kingdom, ⁶Hospital de Sant Pau, Barcelona, Spain, ⁷Université de Lille, CHU Lille, Service de rhumatologie, Lille, France, Lille, France, ⁸Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, ⁹Hospital Universitario Vall d´Hebron, Barcelona, Spain, ¹⁰Fresenius Kabi SwissBioSim, Eysins, Switzerland, ¹¹Fresenius Kabi Biopharma, Eysins, Switzerland, ¹²University of Geneva, Eysins, Switzerland, ¹³Fresenius Kabi Biopharma, Eyzins, France
Background/Purpose: Although most healthcare professionals are convinced of the quality, safety, and favorable economic impact of biosimilars, their routine use is not yet widespread. MSB11456…
Abstract Number: 1345 • ACR Convergence 2025
Upregulated TLR Signaling Identified in Difficult-to-Treat RA: A Propensity Score–Matched Transcriptome Study
YOSHINORI NISHIURA¹, YOSHIHARU SATO², YU NAKAI¹, MOE TOKUNAGA¹, KENTA SHIDAHARA¹ and YOSHINOBU KOYAMA³, ¹Japan Red Cross Okayama Hospital, Okayama-shi, Okayama, Japan, ²DNA Chip Research Inc., Kawasaki-shi, Kanagawa, Japan, ³Japanese Red Cross Okayama Hospital, Okayama, Okayama, Japan
Background/Purpose: Difficult-to-treat rheumatoid arthritis (D2T-RA) represents a clinically challenging RA subset defined by failure to achieve disease control despite multiple conventional and advanced therapies. The…
Abstract Number: 1361 • ACR Convergence 2025
Efficacy of Telitacicept in the treatment of Connective tissue disease-associated interstitial lung disease: A Potential therapeutic option
Mingfang Sun¹, Xue Chen², Ying Zhou², Yanlong Yang², Fei Xiao² and huanzi dai², ¹Daping Hospital, chongqing, China (People's Republic), ²Daping Hospital & Research Institute of Surgery, Army Medical University, Chongqing, PR China., Chongqing, China (People's Republic)
Background/Purpose: Connective tissue disease-associated interstitial lung disease(CTD-ILD) represents a significant cause of mortality among patients. Presently, research on treatment options for CTD-ILD is limited, with…
Abstract Number: 1370 • ACR Convergence 2025
Impact of Six-Month Monitoring Compared to Three-Month Monitoring of Labs for Methotrexate Toxicity
Spencer Simko¹, Sohini Mukherjee², Ray Zhang², Puneet Bajaj³ and Bonnie Bermas⁴, ¹University of Texas Southwestern, Dallas, TX, ²University of Texas Southwestern, Dallas, ³UT Southwestern Medical Center, Dallas, TX, ⁴UTSouthwestern.edu, Dallas, TX
Background/Purpose: Current rheumatology treatment guidelines recommend lab monitoring for methotrexate toxicity at three-month intervals for established patients. We sought to evaluate whether monitoring labs at…
Abstract Number: 1274 • ACR Convergence 2025
Analysis of Vaccination Compliance In Patients With Juvenile Idiopathic Arthritis At The Rheumatology Transitional Consultation
Andres Perez Hurtado¹, Jose Ivorra Cortes², ELENA GRAU GARCIA³, Miguel Simeo Vinaixa⁴, Iago Alcantara Alvarez⁴, Belen Villanueva Manes⁵, Alba Maria Torrat Noves⁶, Daniel Ramos Castro⁷, Pablo Muñoz Martinez⁴, Laura mas sanchez⁸, Berta López Montesinos⁹, Lucía Lacruz Pérez¹⁰ and José Andrés Román Ivorra¹¹, ¹Hospital Universitario y Politècnico La Fe, València, Comunidad Valenciana, Spain, ²Hospital Universitario La Fe, Valencia, Comunidad Valenciana, Spain, ³HUP La Fe, Valencia, Comunidad Valenciana, Spain, ⁴Rheumatology Department. HUP La Fe, Valencia, Spain, ⁵Hospital La Fe, València, Spain, ⁶Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Spain, ⁷Hospital Universitari i Politecnic La Fe, Valencia, Spain, ⁸Hospital Universitario y Politécnico La Fe, Valencia, Comunidad Valenciana, Spain, ⁹Pediatric Rheumatology Department. HUP La Fe, Valencia, Spain, ¹⁰Pediatric Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, ¹¹Hospital Universitari i Politècnic La Fe, Valencia, Spain
Background/Purpose: Juvenile idiopathic arthritis is the most common group of inflammatory rheumatic diseases in childhood. Its early onset and the immunosuppressive treatments used to control…
Abstract Number: 1377 • ACR Convergence 2025
Humanistic Burden of Sjögren’s Disease: A Systematic Review of Treatment Efficacy on Health-Related Quality-of-Life
Esen Akpek¹, Elizabeth Adamson², Lisa Shea², Federico Zazzetti³, Soumya Chakravarty⁴, Sandip Ranjan⁵, Ravi Potluri⁶ and Alexander Keenan², ¹Johns Hopkins Jerome L. Greene Sjögren's Syndrome Center, Baltimore, MD USA, Baltimore, MD, ²Johnson & Johnson, Horsham, PA, USA, Horsham, PA, ³Johnson & Johnson, Horsham, PA, USA, Ambler, PA, ⁴Johnson & Johnson, Horsham, PA, USA; Drexel University College of Medicine, Philadelphia, PA, USA, Villanova, PA, ⁵Putnam Associates, Gurugram, India, Gurugram, India, ⁶Putnam Associates, Boston, MA, USA, Boston, MA
Background/Purpose: Sjögren’s disease (SjD) is a chronic systemic autoimmune disorder that imposes significant clinical, humanistic, and economic burdens on patients. It is associated with multiple…
Abstract Number: 1389 • ACR Convergence 2025
Association Of Dry Eye Severity With Salivary Flow In Patients With Primary Sjögren’s Syndrome
Janett C. Riega-Torres¹, Karina Palomo-Arnaud², Jose Martinez-Delgado³, Fernando Morales-Wong³, Jesus Mohamed-Hamsho³, Valeria Mata-Riega², Irma Cantu-Zapata², Luis Medina-Gomez², Miguel Betancourt-De la Torre², Aritze Chong-Amezcua², Dionicio A. Galarza-Delgado⁴ and Karim Mohamed-Noriega³, ¹Rheumatology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico, ²Hospital Universitario "Dr. José Eleuterio González", Rheumatology, Monterrey, Nuevo León, Monterrey, Nuevo Leon, Mexico, ³Hospital Universitario "Dr. José Eleuterio González", Ofthalmology, Monterrey, Nuevo León, Monterrey, Nuevo Leon, Mexico, ⁴Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico
Background/Purpose: Sjögren’s Syndrome (SS) is a multisystemic autoimmune disease that causes hypofunction of salivary and lacrimal glands, manifesting in xerostomia and xerophthalmia among other systemic…
Abstract Number: 1282 • ACR Convergence 2025
Real-world use of belimumab in childhood-onset SLE in Spain: cross-sectional analysis from a multicenter study (JULES registry)
Alina-Lucica Boteanu¹, Clara Udaondo², Joan Calzada³, Daniel Clemente Garulo⁴, Juan Carlos Nieto Gonzáles⁵, Eugenia Enriquez⁶, inmaculada Calvo Penades⁷, Lourdes Villalobos⁸, Belen Sevilla⁹, Sara Murias¹⁰, Berta Magallares¹¹, Ana Capilla¹², Jaime Arroyo¹³, Beatriz Bravo¹⁴, Gisela Diez-Cordoves¹⁵, Marisol Camacho¹⁶, Genaro grana¹⁷, Juan Jose Bethencourt¹⁸, Pablo Mesa¹⁹, Natalia Palmou²⁰, Mireia Lopez Corbeto²¹, Judith Sanchez²², Maria Isabel Gonzalez²³, isabel Patora Granados bautista²⁴, Clara Moriano²⁵, Diego Dios¹⁷, Lorena Exposito²⁶, Alicia Garcia²⁷, Laura Martin²⁸, David Fernandez²⁹, Laura Trujillo¹⁴, Anahy Maria Brandy³⁰ and CARLOS GUILLEN-ASTETE³¹, ¹H.U. Ramón y Cajal, Madrid, Spain, ²La Paz University Hospital, Madrid, Spain, ³University Hospital Sant Joan de Deu, Barcelona, Spain, ⁴H.U Niño Jesús, Madrid, Spain, ⁵H.U Gregorio Marañón, Madrid, Spain, ⁶Clínica Universidad de Navarra, Madrid, Spain, ⁷Pediatric Rheumatology Department. HUP La Fe, Valencia, Spain, ⁸Ramon y Cajal Hospital, MADRID, Spain, ⁹Division of Pediatrics, Hospital Universitario San Cecilio, Granada, Spain, ¹⁰H.U Central de Asturias, Oviedo, Spain, ¹¹Hospital de Sant Pau, Bareclona, ¹²H.U de La Merced, Sevilla, Spain, ¹³HOSPITAL UNIVERSITARIO LA PAZ, MADRID, ¹⁴H.U Virgen de Las Nieves, Granada, Spain, ¹⁵H. R. U. Malaga, Malaga, Spain, ¹⁶H.U. Virgen del Rocío, Sevilla, Spain, ¹⁷H.U de A Coruña, A Coruña, Spain, ¹⁸H.U. Canarias, Canarias, Spain, ¹⁹H.U Virgen de la Arrixaca, Murcia, Spain, ²⁰H.U. marques de Valdecilla, Santander, Spain, ²¹H.U Vall d´Hebron, Barcelona, Spain, ²²Pediatric Rheumatology Department, Taulí Hospital Universitari-Institut d'Investigació i Innovació Parc Taulí (I³PT-CERCA), Sabadell (Spain)., Sabadell, Spain, ²³H.U. La Fé, Valencia, Spain, ²⁴H.U Toledo, Toledo, Spain, ²⁵Hospital León, LEON, Castilla y Leon, Spain, ²⁶H.U Canarias, Canarias, Spain, ²⁷Rheumatologist, La Laguna, Spain, ²⁸H.R.U Malaga, Malaga, Spain, ²⁹Complejo Hospitalario Universitario de Vigo, Vigo, Galicia, Spain, ³⁰Hospital Germans Trias i Pujol, Badalona, Spain, ³¹H.U Ramón y Cajal, Madrid, Spain
Background/Purpose: SLE is a multisystemic autoimmune disease with several manifestations. Childhood-onset SLE (cSLE) has a more severe disease course than adult-onset SLE, with a higher…
Abstract Number: 1369 • ACR Convergence 2025
Impact of SGLT2 Inhibitors and GLP-1 Agonists on RA Flares in Patients on DMARD Therapy: A Retrospective Study
Shreya Sakthivel¹, Mitch Karpman², Liam Oland³ and Amer Aldamouk⁴, ¹Anne Arundel Medical Center, Washington DC, DC, ²Anne Arundel Medical Center, Annapolis, ³Saba University School of Medicine, Annapolis, ⁴Anne Arundel Medical Center, Washington, DC
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease driven by T- and B-cell activation and pro-inflammatory cytokines such as TNF-α and IL-6 and is…
Abstract Number: 1382 • ACR Convergence 2025
Interstitial lung disease in primary sjögren syndrome: pathochrony, seronegative cases, and Risk of progressive pulmonary fibrosis
Delia Reina¹, Paula Estrada-Alarcón², Daniel Roig-Vilaseca¹, Dacia Cerdà¹, Vanessa Navarro-Angeles³, oscar Camacho¹, Sergi Herdia⁴, Marta lópez-Gómez¹, Silvia Gacía-Díaz¹, Paola Vidal Montal⁵, Pol Maymó-Paituvi⁶, martí Aguilar-Coll⁷ and Javier Narváez⁸, ¹Complex Hospitalari Universitari Moisès Broggi, Barcelona, Spain, ²Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ³Department of Rheumatology, Complex Universitari Hospitalari Moisès Broggi, Sant Joan Despí, Barcelona, Spain, Sant Joan Despí, Barcelona, Spain, ⁴Complex Hospitalari Moisès Broggi, Barcelona, Spain, ⁵Bellvitge University Hospital, Barcelona, Spain, ⁶Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, ⁷Hospital Universitari de Bellvitge, Barcelona, Spain, ⁸Hospital Universitari de Bellvitge, L'Hospitalet; Barcelona, Barcelona, Spain
Background/Purpose: Sjögren’s disease (SjD) is a chronic autoimmune disorder primarily targeting exocrine glands. A significant extraglandular manifestation is interstitial lung disease (ILD), which contributes to…
Abstract Number: 1371 • ACR Convergence 2025
Effect of bDMARDs and tsDMARDS on diffuse interstitial lung disease associated with rheumatoid arthritis: systematic review and meta-analysis
Stéphane HILLIQUIN¹, Enrico VISMARA¹, Virginia BERLENGIERO² and Jérôme AVOUAC³, ¹Département de Rhumatologie, Hôpital Cochin, Assistance publique des Hôpitaux de Paris, Université Paris-Cité, Paris, France, PARIS, France, ²Rheumatoloy Department, Cochin Hospital, PARIS, France, ³Rheumatology department, Cochin hospital, Paris, France
Background/Purpose: Interstitial lung disease (ILD) is a severe complication of rheumatoid arthritis (RA), associated with increased morbidity and mortality. The pulmonary safety of biologic (bDMARDs)…
Abstract Number: 1296 • ACR Convergence 2025
Liver Biopsy Findings in Pediatric SLE: A Large Tertiary Center Experience
Meredith Rae¹, Dawn Gist², Kaylani Patel³, Krupa Mysore³, Andrea Ramirez², Marietta De Guzman² and Eyal Muscal², ¹Baylor College of Medicine/Texas Children's Hospital, Houston, TX, ²Baylor College of Medicine, Houston, TX, ³Baylor College of Medicine/Texas Children's Hospital, Houston
Background/Purpose: Distinguishing lupus hepatitis (LH) from autoimmune hepatitis (AIH) in SLE is clinically challenging but critical for guiding treatment duration. The mechanisms differ; AIH results…
Abstract Number: 1380 • ACR Convergence 2025
Phenotyping Neuropathic Pain in Sjögren’s Disease: A Cluster-Based Approach
Beatrice Dei¹, Stefano Donati¹, Gaetano La Rocca², Giovanni Fulvio¹, Federico Fattorini¹, Antonello Sulis¹, Michele Moretti¹, Elena Elefante¹, Francesco Ferro³, Giulia Ricci⁴, Marta Mosca⁵ and Chiara Baldini⁵, ¹Rheumatology Unit, University of Pisa, Pisa, Toscana, Italy, ²University of Pisa, Rheumatology Unit, Pisa, Pisa, Italy, ³Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, ⁴Neurology Unit, University of Pisa, Pisa, Toscana, Italy, ⁵University of Pisa, Pisa, Pisa, Italy
Background/Purpose: Neuropathic pain (NeP) is increasingly recognized as a relevant symptom domain in primary Sjögren’s disease (SjD), contributing to the disease burden beyond glandular involvement.…
Abstract Number: 1379 • ACR Convergence 2025
Renal tubular acidosis in Sjögren’s disease and non-Sjögren’s sicca in an Oklahoma cohort
Biji T Kurien¹, Martha Tsaliki² and R Hal Scofield¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²OMRF, Oklahoma City, OK
Background/Purpose: Renal involvement in primary Sjögren’s disease (pSjD) is a well-known extraglandular manifestation with a prevalence of 5-14% in several studies. Mostly, it affects the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].